X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (57) 57
index medicus (37) 37
humans (32) 32
female (31) 31
cancer (20) 20
chemotherapy (19) 19
aged (18) 18
middle aged (18) 18
ovarian cancer (17) 17
carcinoma (16) 16
bevacizumab (15) 15
ovarian neoplasms - drug therapy (15) 15
adult (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
obstetrics & gynecology (11) 11
cervical cancer (10) 10
hematology, oncology and palliative medicine (10) 10
angiogenesis (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
disease-free survival (9) 9
gynecologic-oncology-group (9) 9
neoplasm recurrence, local - drug therapy (9) 9
research (9) 9
cancer therapies (8) 8
clinical trials (8) 8
ovarian neoplasms - pathology (8) 8
paclitaxel - administration & dosage (8) 8
prognosis (8) 8
solid tumors (8) 8
tumors (8) 8
analysis (7) 7
care and treatment (7) 7
cisplatin (7) 7
health aspects (7) 7
paclitaxel (7) 7
treatment outcome (7) 7
abridged index medicus (6) 6
aged, 80 and over (6) 6
drug therapy (6) 6
follow-up studies (6) 6
medicine, general & internal (6) 6
mutation (6) 6
neoplasm staging (6) 6
ovarian neoplasms - genetics (6) 6
survival (6) 6
carcinoma, ovarian epithelial (5) 5
drug administration schedule (5) 5
human papillomavirus (5) 5
medicine & public health (5) 5
neoplasms, glandular and epithelial - drug therapy (5) 5
oncology, experimental (5) 5
recurrent (5) 5
survival rate (5) 5
article (4) 4
brca1 protein - genetics (4) 4
brca2 protein - genetics (4) 4
carboplatin (4) 4
diagnosis (4) 4
double-blind method (4) 4
germ-line mutation (4) 4
multicenter (4) 4
open-label (4) 4
papillomavirus infections (4) 4
patients (4) 4
platinum (4) 4
prospective studies (4) 4
relapse (4) 4
therapy (4) 4
trial (4) 4
uterine cervical neoplasms - drug therapy (4) 4
uterine cervix (4) 4
vascular endothelial growth factor (4) 4
angiogenesis inhibitors - administration & dosage (3) 3
animals (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
antineoplastic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast-cancer (3) 3
carboplatin - administration & dosage (3) 3
cervix (3) 3
cisplatin - administration & dosage (3) 3
clinical medicine (3) 3
diseases (3) 3
dna-repair (3) 3
double-blind (3) 3
doxorubicin - administration & dosage (3) 3
drug resistance, neoplasm (3) 3
endometrial cancer (3) 3
epithelial ovarian (3) 3
fallopian-tube (3) 3
genes, brca1 (3) 3
genes, brca2 (3) 3
human papilloma virus (3) 3
infusions, intravenous (3) 3
inhibition (3) 3
male (3) 3
management (3) 3
medical and health sciences (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2014
This thesis explores the Spanish authors, Ana María Matute (1926-), Rosa Montero (1952-), and Lucía Etxebarri a (1966-) in the context of the socio-political... 
Dissertation
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | BRCA MUTATION | POLY(ADP-RIBOSE) POLYMERASE | RANDOMIZED PHASE-2 | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | PROSTATE-CANCER | INHIBITORS | DNA-REPAIR | NEGATIVE BREAST-CANCER | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 245 - 251
Journal Article
by Vergote, Ignace and Scambia, Giovanni and O'Malley, David and O'Malley, David M and Van Calster, Ben and Park, Sang-Yoon and Park, Sang Yoon and del Campo, Josep M and Meier, Werner and Bamias, Aristotelis and Colombo, Nicoletta and Wenham, Robert M and Wenham, Robert and Covens, Allan and Covens, Al and Marth, Christian and Raza Mirza, Mansoor and Kroep, Judith and Kroep, Judith R and Ma, Haijun and Pickett, Cheryl A and Monk, Bradley J and Monk, Bradley and Song, Yong Sang and Makarova, Yulia and Trinidad, Joshua and Ngan, Hextan Yuen Sheung and Aravantinos, Gerasimos and Nam, Joo-Hyun and Gorbunova, Vera and Krikunova, Ludmila and Bae, Duk-Soo and Arija, Jose Angel Arranz and Mirza, Mansoor Raza and Zamagni, Claudio and Papandreou, Christos and Raspagliesi, Francesco and Lisyanskaya, Alla and Benzaquen, Ana Oaknin and Tognon, Germana and Ortega, Eugenia and Herraez, Antonio Casado and Buscema, Joseph and Green, Andrew and Burger, Robert and Sakaeva, Dina and Sanchez, Andres Redondo and Ghamande, Sharad and King, Laurel and Petru, Edgar and Peen, Ulla and Takeuchi, Satoshi and Ushijima, Kimio and Martin, Antonio Gonzalez and Kamelle, Scott and Carney, Michael and Forget, Frédéric and Bentley, James and Sehouli, Jalid and Zola, Paolo and Kato, Hidenori and Fadeeva, Natalya and Gotovkin, Evgeny and Vladimirov, Vladimir and Marin, Margarita Romeo and Alia, Eva Guerra and Shahin, Mark and Bhoola, Snehalkumar and Tewari, Krishnansu and Anderson, Daniel and Anderson, Jeanne and Honhon, Brigitte and Pelgrims, Joseph (Gino) and Oza, Amit and Jimenez, Jesus Garcia-Donas and Hansen, Vincent and Benjamin, Ivor and Renard, Vincent and Van den Bulck, Heidi and Haenle, Claudia and Koumakis, Georgios and Yokota, Harushige and Popov, Vadim and Bradley, William and Reid, Robert and Reid, Gary and McNamara, Donna and Friedman, Richard and Barlin, Joyce and Spirtos, Nicola and Chapman, Julia and Sevelda, Paul and Huizing, Manon and Lamot, Caroline and Goffin, Frédéric and Hondt, Lionel D and Spadafora, Silvana and Rautenberg, Beate and Reimer, Toralf and Möbus, Volker and ... and TRINOVA-3 ENGOT-ov2 GOG-3001 Inves and TRINOVA-3/ENGOT-ov2/GOG-3001 investigators
The Lancet Oncology, ISSN 1470-2045, 06/2019, Volume 20, Issue 6, pp. 862 - 876
Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has... 
WOMEN | THERAPY | INHIBITION | ANGIOGENESIS | ONCOLOGY | FUNCTIONAL ASSESSMENT | BEVACIZUMAB | SUPPRESSION | TUMOR-GROWTH | AMG 386 | CHEMOTHERAPY | Care and treatment | Analysis | Carboplatin | Clinical trials | Product development | Ovarian cancer | Cancer
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 5543 - 5543
Conference Proceeding
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 799 - 808
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2014, Volume 370, Issue 8, pp. 734 - 743
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 301 - 311
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 26, pp. 2495 - 2505
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum | Index Medicus | Abridged Index Medicus
Journal Article